Regulators Have Called for Alternatives to Animal Testing
Global health agencies, including the MHRA, have adopted a plan to shift medicine development toward non-animal methods.
Updated on Oct. 5, 2026 in Veterinary Medicine
Live Poll
Should regulatory authorities prioritize non-animal testing methods for the development of new human medicines?
The International Coalition of Medicines Regulatory Authorities has officially adopted a joint statement calling for the replacement of animal testing in medicine development. This initiative spans the entire development lifecycle, from initial research screening through final post-authorisation activities.
Why it matters
By prioritizing non-animal testing methods, regulators aim to reduce reliance on traditional animal models for medical safety and efficacy trials. This shift is expected to increase reliance on advanced technological solutions throughout the drug development process.
The ICMRA coalition intends to replace animal testing across the entire pipeline of medicine development. The greatest reduction in animal usage is expected to come from implementing non-animal methods specifically for batch release testing.
The players
MHRA
An executive agency of the UK Department of Health and Social Care responsible for regulating medicines and medical devices.
ICMRA
The International Coalition of Medicines Regulatory Authorities, a global network of regulators focused on coordinating medical standards.
The details
Regulators are moving toward the adoption of New Approach Methodologies to evaluate medical data. Scientists at the MHRA are currently researching advanced technologies including 3D bioprinted tissues, organ-on-a-chip systems, and AI-driven predictive models. Agencies will now clarify how non-animal data is assessed to increase confidence among developers, only approving animal testing for batch release when no other equivalent method exists.
Timeline
March 2026: The MHRA announced its commitment to phase out animal testing in medicine development.
October 5, 2026: The International Coalition of Medicines Regulatory Authorities published the joint statement.
The Home Front
This move represents a significant departure from traditional pharmaceutical testing standards established over the last century. It follows the precedent set by the MHRA's New Approach Methodologies guidance, which established the framework for moving toward non-animal testing models.
Pet owners and families interested in medical innovation should note that this shift focuses on the development of future human and veterinary medicines. While this change does not impact immediate home medical supplies, it represents a long-term evolution in how products are tested for safety.
The takeaway
The transition away from animal testing marks a major shift in how medical treatments are developed and approved worldwide. Families tracking medical advancements can monitor the progress of non-animal alternatives like 3D bioprinted tissues as these methods continue to gain regulatory support.
Further reading
For more on the evolving standards for animal care and health research, see our Veterinary Medicine section.
More information
Review the full joint statement and coalition details on the ICMRA official website.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Should regulatory authorities prioritize non-animal testing methods for the development of new human medicines?
